[Federal Register Volume 70, Number 197 (Thursday, October 13, 2005)]
[Notices]
[Pages 59779-59780]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E5-5597]


=======================================================================
-----------------------------------------------------------------------

NUCLEAR REGULATORY COMMISSION

[Docket No. 030-35882]


Notice of Availability of Environmental Assessment and Finding of 
No Significant Impact for License Amendment for Purdue Pharma, L.P.'s 
Facility in Cranbury, NJ

AGENCY: Nuclear Regulatory Commission.

ACTION: Notice of availability.

-----------------------------------------------------------------------

FOR FURTHER INFORMATION CONTACT: Betsy Ullrich, Commercial and R&D 
Branch, Division of Nuclear Materials Safety, Region I, 475 Allendale 
Road, King of Prussia, Pennsylvania 19406, telephone (610) 337-5040, 
fax (610) 337-5269; or by e-mail: [email protected].

SUPPLEMENTARY INFORMATION:

I. Introduction

    The Nuclear Regulatory Commission (NRC) is considering issuing a 
license amendment to Purdue Pharma, L.P. for Materials License No. 29-
30698-01, to authorize release of its facility in Edgewater, New 
Jersey, for unrestricted use. NRC has prepared an Environmental 
Assessment (EA) in support of this action in accordance with the 
requirements of 10 CFR part 51. Based on the EA, the NRC has concluded 
that a Finding of No Significant Impact (FONSI) is appropriate.

II. EA Summary

    The purpose of the proposed action is to authorize the release of 
two sections of the licensee's Cranbury, New Jersey, facility for 
unrestricted use. Purdue Pharma, L.P. was authorized by NRC from 2002 
to use radioactive materials for research and development purposes at 
the site. On April 21, 2005, Purdue Pharma, L.P. requested that NRC 
release two sections of the facility for unrestricted use. Purdue 
Pharma, L.P. has conducted surveys of the two sections of the facility 
and provided information to the NRC to demonstrate that the site meets 
the license termination criteria in subpart E of 10 CFR part 20 for 
unrestricted use.
    The NRC staff has prepared an EA in support of the license 
amendment. The two sections of the facility were remediated and 
surveyed prior to the licensee requesting the license amendment. The 
NRC staff has reviewed the information and final status survey 
submitted by Purdue Pharma, L.P. Based on its review, the staff has 
determined that there are no additional remediation activities

[[Page 59780]]

necessary to complete the proposed action. Therefore, the staff 
considered the impact of the residual radioactivity at the facility and 
concluded that since the residual radioactivity meets the requirements 
in subpart E of 10 CFR part 20, a Finding of No Significant Impact is 
appropriate.

III. Finding of No Significant Impact

    The staff has prepared the EA (summarized above) in support of the 
license amendment to terminate the license and release the facility for 
unrestricted use. The NRC staff has evaluated Purdue Pharma, L.P.'s 
request and the results of the surveys and has concluded that the 
completed action complies with the criteria in Subpart E of 10 CFR part 
20. The staff has found that the radiological environmental impacts 
from the action are bounded by the impacts evaluated by NUREG-1496, 
Volumes 1-3, ``Generic Environmental Impact Statement in Support of 
Rulemaking on Radiological Criteria for License Termination of NRC-
Licensed Facilities'' (ML042310492, ML042320379, and ML042330385). 
Additionally, no non-radiological or cumulative impacts were 
identified. On the basis of the EA, the NRC has concluded that the 
environmental impacts from the action are expected to be insignificant 
and has determined not to prepare an environmental impact statement for 
the action.

IV. Further Information

    Documents related to this action, including the application for the 
license amendment and supporting documentation, are available 
electronically at the NRC's Electronic Reading Room at http://www.nrc.gov/reading-rm/adams.html. From this site, you can access the 
NRC's Agencywide Document Access and Management System (ADAMS), which 
provides text and image files of NRC's public documents. The ADAMS 
accession numbers for the documents related to this Notice are: 
Environmental Assessment Related to an Amendment of U.S. Nuclear 
Regulatory Commission Materials License No. 29-30698-01, Issued to 
Purdue Pharma, L.P. (ML052780150), the Purdue Pharma, L.P. letter dated 
April 21, 2005 (ML052590192) and the Purdue Pharma, L.P. letter dated 
June 30, 2005 (ML052590186). Persons who do not have access to ADAMS or 
who encounter problems in accessing the documents located in ADAMS, 
should contact the NRC PDR Reference staff by telephone at (800) 397-
4209 or (301) 415-4737, or by e-mail to [email protected].
    Documents related to operations conducted under this license not 
specifically referenced in this Notice may not be electronically 
available and/or may not be publicly available. Persons who have an 
interest in reviewing these documents should submit a request to NRC 
under the Freedom of Information Act (FOIA). Instructions for 
submitting a FOIA request can be found on the NRC's Web site at http://www.nrc.gov/reading-rm/foia/foia-privacy.html.

    Dated at King of Prussia, Pennsylvania, this 5th of October, 
2005.

    For the Nuclear Regulatory Commission.
James P. Dwyer,
Chief, Commercial and R&D Branch, Division of Nuclear Materials Safety, 
Region I.
 [FR Doc. E5-5597 Filed 10-12-05; 8:45 am]
BILLING CODE 7590-01-P